|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1993-2-22
|
|
pubmed:abstractText |
Combination therapy with systemically administered interleukin-2 (IL-2) and interferon alpha (IFN-alpha) has resulted in long-term objective remissions in 30% of patients with metastatic renal cell carcinoma (RCC), but toxic effects are clinically significant.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
207-16
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8423625-Animals,
pubmed-meshheading:8423625-Carcinoma, Renal Cell,
pubmed-meshheading:8423625-Gene Therapy,
pubmed-meshheading:8423625-Genes, myc,
pubmed-meshheading:8423625-Histocompatibility Antigens Class I,
pubmed-meshheading:8423625-Humans,
pubmed-meshheading:8423625-Immunotherapy, Active,
pubmed-meshheading:8423625-Interferon-alpha,
pubmed-meshheading:8423625-Interleukin-2,
pubmed-meshheading:8423625-Kidney Neoplasms,
pubmed-meshheading:8423625-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:8423625-Lymphocyte Activation,
pubmed-meshheading:8423625-Mice,
pubmed-meshheading:8423625-Transfection,
pubmed-meshheading:8423625-Tumor Cells, Cultured
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
|
|
pubmed:affiliation |
Department of Surgery, UCLA School of Medicine 90024.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
